Domain

Smobler's NOVA 2024 Gets Bigger and Bolder in the Lone Star State

Retrieved on: 
Tuesday, March 12, 2024

AUSTIN, Texas, March 12, 2024 /PRNewswire/ -- Smobler, a leading metaverse architect headquartered in Singapore, proudly announces the much-anticipated launch of NOVA 2024: Austin Edition. Following the resounding success of its inaugural edition in Singapore last year, NOVA 2024 will dazzle attendees at the Austin Central Public Library on March 12th as part of the Asia x Austin International Market Summit and as an official SXSW event.

Key Points: 
  • NOVA is a celebration of the communities that are created by and connected with the Smobler ecosystem.
  • It is an in-real-life (IRL) invitation to the global community to converge, interact, and forge collaborations within the burgeoning open metaverse.
  • Mark Duval, GAACC President and CEO says, "The magic of the metaverse happens when communities flourish and people truly connect.
  • NOVA 2024: Austin Edition promises an unforgettable evening in innovation, collaboration, and celebration.

Solaris Announces Cooperation Agreement with Interprovincial Federation of Shuar Centers and the Alliance for Entrepreneurship and Innovation of Ecuador

Retrieved on: 
Friday, March 1, 2024

VANCOUVER, British Columbia, March 01, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a trilateral cooperation agreement with the Interprovincial Federation of Shuar Centers (“FICSH”) and the Alliance for Entrepreneurship and Innovation (“AEI”) of Ecuador, with the signing ceremony to take place over PDAC.

Key Points: 
  • VANCOUVER, British Columbia, March 01, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a trilateral cooperation agreement with the Interprovincial Federation of Shuar Centers (“FICSH”) and the Alliance for Entrepreneurship and Innovation (“AEI”) of Ecuador, with the signing ceremony to take place over PDAC.
  • FICSH is the highest authority and largest Shuar indigenous organization legally established by statute of the Ministry of Social Welfare of Ecuador in 1964 and includes 50 associations comprising 500 Shuar communities and approximately 143,000 Shuar indigenous people.
  • AEI is an independent non-profit dedicated to promoting entrepreneurship and innovation as the basis for the productive development of Ecuador.
  • The organization represents a network of public, private and academic actors of which Solaris has been a member since 2021.

New Domain Blocking Service to Revolutionize Online Brand Protection

Retrieved on: 
Thursday, February 29, 2024

TEMPE, Ariz., Feb. 29, 2024 /PRNewswire/ -- GlobalBlock, a revolutionary domain name blocking service has just launched, providing unprecedented protection by blocking available domain names that match the brand and preventing purchase by bad actors.

Key Points: 
  • TEMPE, Ariz., Feb. 29, 2024 /PRNewswire/ -- GlobalBlock, a revolutionary domain name blocking service has just launched, providing unprecedented protection by blocking available domain names that match the brand and preventing purchase by bad actors.
  • Using this service, brand owners can simplify domain portfolio management and reduce the impact of bad actors online.
  • Ben Anderson, the BSA Product Director, said online brand protection is increasingly challenging to manage in today's complex online world.
  • Brian Lonergan, Vice President of Product at Identity Digital, the operator of the widely adopted Digital Protected Marks List (DPML) service, said the unified approach GlobalBlock offers brand owners would revolutionize online brand protection.

Squarespace Announces Fourth Quarter and Full Year 2023 Financial Results and $500 Million Share Repurchase Authorization

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Squarespace, Inc. (NYSE: SQSP), the design-driven platform helping entrepreneurs build brands and businesses online, today announced results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • "Squarespace delivered a record fourth quarter that exceeded our expectations across the board," said Nathan Gooden, CFO of Squarespace.
  • Total revenue grew 18% year over year to $270.7 million in the fourth quarter, compared with $228.8 million in the fourth quarter of 2022, and 16% in constant currency.
  • Total bookings grew 23% year over year to $286.1 million in the fourth quarter, compared to $232.1 million in the fourth quarter of 2022.
  • Adjusted EBITDA increased to $64.7 million in the fourth quarter, compared with $63.1 million in the fourth quarter of 2022.

IKEA U.S. announces plans to open four new-format stores in 2024 and shares progress made in FY23

Retrieved on: 
Wednesday, January 17, 2024

CONSHOHOCKEN, Pa., Jan. 17, 2024 /PRNewswire/ -- Today, alongside the release of the 2023 Annual Summary, IKEA U.S. announced that four Plan & order point with Pick-up locations will open across the country in 2024. The Annual Summary shares strides the company made in affordability, sustainable practices, automation, and equity and inclusion; and these strategic expansions showcase how IKEA remains committed to making the brand more accessible, convenient and affordable for the many.

Key Points: 
  • CONSHOHOCKEN, Pa., Jan. 17, 2024 /PRNewswire/ -- Today, alongside the release of the 2023 Annual Summary, IKEA U.S. announced that four Plan & order point with Pick-up locations will open across the country in 2024.
  • With the addition of the IKEA Pick-up point, customers will be able to collect their purchases when and where it's convenient for them.
  • In addition to new locations announced today, IKEA U.S. will open Plan & order points with Pick-up in Annapolis and Gaithersburg, Maryland, Katy, Texas and more.
  • View the full IKEA U.S. FY23 Annual Summary here for more details on how IKEA is creating a better everyday life for the many.

Willow Bridge Property Company Celebrates Prestigious NAIOP Award for Domain CityGate, 285-Unit Apartment Development in Naperville, IL

Retrieved on: 
Thursday, December 7, 2023

NAIOP, the Commercial Real Estate Development Association, is the leading organization for developers, owners and related professionals in office, industrial and mixed-use real estate.

Key Points: 
  • NAIOP, the Commercial Real Estate Development Association, is the leading organization for developers, owners and related professionals in office, industrial and mixed-use real estate.
  • The recognition comes as a testament to the exceptional quality and innovation showcased by Domain CityGate, marking a significant achievement for Willow Bridge Property Company and all parties involved in its success.
  • Joe Segobiano, Senior Vice President of Development at Willow Bridge, expressed his enthusiasm, stating, “We are thrilled to see Domain CityGate recognized as the Multifamily Development of the Year.
  • Willow Bridge Property Company extends its gratitude to NAIOP for recognizing Domain CityGate as the Multi-Family Development of the Year, further solidifying their commitment to excellence in real estate development and community enhancement.

Energy Domain Joins Forces with Palace Road Partners

Retrieved on: 
Wednesday, November 8, 2023

Founded in 2021 by Ryan Vinson and the 5Ms Technologies team that created MineralWare and Energy Freelance (now EnergyHire), Energy Domain has already achieved significant traction.

Key Points: 
  • Founded in 2021 by Ryan Vinson and the 5Ms Technologies team that created MineralWare and Energy Freelance (now EnergyHire), Energy Domain has already achieved significant traction.
  • Just a few miles down the road in Dallas, new private capital advisory firm Palace Road Partners (PRP) saw the same opening and presented Energy Domain with an opportunity to provide cost and efficiency benefits to shared high value clients.
  • As PRP Co-Founder Blake Van Patten explained, “Energy Domain has successfully bypassed the traditional oil and gas markets, getting deals up on their site quickly and efficiently.
  • Said Van Patten, “One of the things we're most excited about is working with the team at Energy Domain.

Squarespace Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- Squarespace, Inc. (NYSE: SQSP), the design-driven platform helping entrepreneurs build brands and businesses online, today announced results for the third quarter ended September 30, 2023.

Key Points: 
  • NEW YORK, Nov. 7, 2023 /PRNewswire/ -- Squarespace, Inc. (NYSE: SQSP), the design-driven platform helping entrepreneurs build brands and businesses online, today announced results for the third quarter ended September 30, 2023.
  • Squarespace Refresh 2023, announced in October, marks one of the strongest years of product releases in our history."
  • Total bookings grew 18% year over year to $267.0 million in the third quarter, compared to $225.5 million in the third quarter 2022.
  • For the fourth quarter of fiscal year 2023, Squarespace currently expects:
    Revenue of $261 million to $264 million, or year-over-year growth of 14% to 16%.

AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO

Retrieved on: 
Wednesday, November 1, 2023

THOUSAND OAKS, Calif., Nov. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics. More than 20 abstracts will be presented during the American College of Rheumatology (ACR) Convergence 2023, taking place Nov. 10-15, in San Diego.

Key Points: 
  • Abstract #2161, Poster Session C: RA – Treatments Poster III, Tuesday, Nov. 14 from 9-11am PST
    Outcomes in Patients With Rheumatoid Arthritis Initiating Therapy With Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Abstract #0441, Poster Session A: RA – Treatments Poster I, Sunday, Nov. 12 from 9-11am PST
    Treatment-Emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
    Abstract #0236, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
    Abstract #0237, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0239, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0242, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
    Abstract #1102, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1103, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1107, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1108, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Real-world Trends in the Use of Immunomodulation as Co-Therapy to Pegloticase: Claims-Based Findings Since 2016
    Abstract #1123, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1145, Poster Session B: Miscellaneous Rheumatic & Inflammatory Diseases Poster II, Monday, Nov. 13 from 9-11am PST
    Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies
    Abstract #1691, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 5-5:10pm PST
    Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
    Abstract #1690, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 4:45-4:55pm PST
    Abstract #0966, Poster Session B: Epidemiology & Public Health Poster II, Monday Nov. 13 from 9-11am PST
    Abstract #1041, Poster Session B: Imaging of Rheumatic Diseases Poster I, Monday Nov. 13 from 9-11am PST
    Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients With Early Oligoarticular Psoriatic Arthritis: 16-Week Results From FOREMOST
    Abstract #1413, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Abstract #1414, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
    Abstract #2528, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:15-4:25pm PST
    Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2529, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:30-4:40pm PST
    Comparative Effectiveness of Denosumab versus Alendronate among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2008, Poster Session C: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0683, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0684, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0685, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0686, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #2379, Poster Session C: Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0171, Poster Session A: Health Services Research Poster I, Sunday, Nov. 12 from 9-11am PST
    Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren's Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
    Abstract #1636, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Abstract #1638, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren's Disease: Results from a Multinational, Real-World Survey
    Abstract #1369, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjögren's Syndrome
    Abstract #1379, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Disease Burden of Patients with Primary Sjögren's Disease: Results from a Multinational Real-World Survey
    Abstract #2179, Poster Session C: Sjögren's Syndrome – Basic & Clinical Science Poster II, Tuesday, Nov. 14 from 9-11am PST
    Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis
    Abstract #0688, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST

CIM Group and Partner Acquire Onyx183 Apartment Community in Austin

Retrieved on: 
Tuesday, October 10, 2023

CIM Group and its partner announced today the acquisition of Onyx183, a 390-unit apartment community located at 6800 McNeil Dr. in Austin, Texas.

Key Points: 
  • CIM Group and its partner announced today the acquisition of Onyx183, a 390-unit apartment community located at 6800 McNeil Dr. in Austin, Texas.
  • Onyx183 comprises 390 residences, configured as one-, two- and three-bedroom floorplans, spanning over 21 acres in the highly desirable Parmer Corridor of Northwest Austin.
  • In addition, the community is located within a 10-minute drive of the Domain, and 20-minute drive of Downtown Austin.
  • CIM Group was a co-developer of the Seaholm Power Plant mixed-use redevelopment as well as The Independent luxury condominium tower.